Maxwell Biotech Venture Fund’s portfolio company Infectex Receives Russian Regulator’s Approval to Conduct Pivotal Clinical Trial for Sequella’s Antibiotic, SQ109, for Tuberculosis

SQ109 will be evaluated for efficacy on multi-drug resistant patients Sequella, a clinical-stage pharmaceutical company focused on commercializing novel antibiotics to treat life-threatening infectious diseases, licensed the late-stage development and commercialization...

Infectex, a portfolio company of Maxwell Biotech Venture Fund, established with the participation of RVC develops an innovative drug SQ109 for the multidrug-resistant tuberculosis (MDR-TB) treatment.

A Skolkovo resident Infectex, a portfolio company of Maxwell Biotech Venture Fund, established with the participation of RVC develops an innovative drug SQ109 for the multidrug-resistant tuberculosis (MDR-TB) treatment together with an American biotech company...

Sergey Borisov, Infectex' scientific advisor, about the company's innovative anti-TB drug SQ109

Maxwell Biotech Venture Fund’s Portfolio Company Infectex Enrolls First Patients in Pivotal Clinical Trial of SQ109 for Multi-Drug Resistant Tuberculosis (MDR-TB)

Infectex, a Russian biotech company in Maxwell Biotech Venture Fund’s portfolio announced today enrollment of the first patients in its Phase IIb-III clinical trial of SQ109 for MDR-TB. Infectex was founded in 2011 to develop and commercialize innovative...